Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SAHH-mediated homocysteine dysregulation drives diabetic retinopathy progression through ferroptosis-dependent mechanisms.

Experimental cell research·2026

Same author

Encephalomyocarditis virus evades IFN-mediated antiviral response by RNF149 targeting JAK1 for ubiquitination and degradation.

Virulence·2026

Same author

Ultra-compact wavelength-division (de)multiplexer on 4H-silicon-carbide-on-insulator platform via inverse design.

Optics letters·2026

Same author

Validity of classical Lorentz reciprocity theorem under nonclassical electromagnetic boundary condition for mesoscale metallic nanostructures.

Optics express·2026

Same author

Sulfonyl-Directed Photoinduced Dehydro-Diels-Alder Reaction of Aryl Maleimides: Enabling Regioselective Naphthalene Synthesis.

JACS Au·2026

Same author

Kinetic and Macroscopic Growth of Methane Hydrate Formation in Maltodextrin-Amino Acid Composite Systems.

Langmuir : the ACS journal of surfaces and colloids·2025

Search research articles

Related Experiment Video

Updated: Aug 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptor T cells applied to solid tumors.

Zhongguo Zhou^1,2, Can Tao³, Jianting Li²

¹School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Frontiers in Immunology

|November 17, 2022

Summary

This summary is machine-generated.

Chimeric antigen receptor T cell (CAR-T) therapy shows promise for solid tumors. This review highlights advancements, challenges, and novel strategies for CAR-T cell therapy in solid tumors, aiming to inspire clinical applications.

Keywords:

CAR T cell therapy antigenheterogeneity crispr screens neoantigen progenitor-like T cell solid tumor tumor microenvironment

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Aug 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor T cell (CAR-T) therapy is a novel immunotherapy that engineers T cells to target tumor antigens.
CAR-T therapy has shown success in hematologic malignancies but faces challenges in solid tumors.
Obstacles include the immunosuppressive tumor microenvironment and lack of specific tumor antigens.

Purpose of the Study:

To review advancements in CAR-T cell therapy for solid tumors.
To summarize challenges and novel interventions for overcoming barriers.
To discuss future directions and potential clinical applications.

Main Methods:

Review of current literature on CAR-T cell therapy in solid tumors.
Analysis of engineering and pharmaceutical strategies to enhance efficacy.
Discussion of emerging technologies like CRISPR-based modifications.

Main Results:

CAR-T therapy faces significant hurdles in solid tumors, including immune suppression and target specificity.
Novel engineering approaches and pharmaceutical interventions are being developed to address these challenges.
Emerging strategies like CRISPR screens and progenitor-derived CAR-T cells show future potential.

Conclusions:

CAR-T cell therapy holds promise for solid tumors, but significant challenges remain.
Continued research into novel engineering and therapeutic strategies is crucial for clinical translation.
This review aims to guide researchers and clinicians in developing effective CAR-T therapies for solid tumors.